Combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site: A Minnie Pearl Cancer Research Network phase II trial

Cancer

Volumn 104, Issue 9, 2005, Pages 1992-1997

  Hainsworth, John D ^a   Spigel, David R ^a   Raefsky, Eric L ^a   Kuzur, Michel E ^a   Yost, Kathleen ^b   Kommor, Michael ^c   Litchy, Sharlene ^a   Greco, F Anthony ^a  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b Grand Rapids CCOP   (United States)

^c Blood Disorders and Cancer ^*  (United States)

Author keywords

Combination chemotherapy; Gemcitabine; Irinotecan; Phase II trial; Unknown primary site

Indexed keywords

CA 19-9 ANTIGEN; GEMCITABINE; IRINOTECAN;

ADULT; AGED; ALOPECIA; ARTICLE; BLEEDING; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RESEARCH; CARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG ACTIVITY; DRUG EFFICACY; DRUG TOLERANCE; FATIGUE; FEMALE; FEVER; HUMAN; IDIOPATHIC DISEASE; INFECTION; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 27244450505     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21416     Document Type: Article

References (10)

1. Hainsworth JD, Erland JB, Kalman LA, et al. Carcinoma of unknown primary site: treatment with one-hour paclitaxel, carboplatin, and extended schedule etoposide. J Clin Oncol. 1997;15:2385-2393.
2. Greco FA, Gray J, Burris HA, et al. Taxane-based chemotherapy in patients with carcinoma of unknown primary site. Cancer J. 2001;7:203-212.
3. Briasoulis E, Kalofonos H, Bafaloukos D, et al. Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group study. J Clin Oncol. 2000;18:3101-3107.
4. Mukai H, Watanake T, Ando M, et al. A safety and efficacy trial of docetaxel and cisplatin in patients with cancer of unknown primary [abstract 2597]. Proc Am Soc Clin Oncol. 2003;22:646.
5. Culine S, Lortholary A, Voigt J-J, et al. Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study-trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol. 2003;21:3479-3482.
6. Hainsworth JD, Burris HA, Calvert SW, et al. Gemcitabine in the second-line therapy of patients with carcinoma of unknown primary site: a phase II trial of the Minnie Pearl Cancer Research Network. Cancer Invest. 2001;19:335-339.
7. Rocha Lima CM, Savarese D, Bruckner H, et al. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol. 2002;20: 1182-1189.
8. Greco FA, Rodriguez GI, Shaffer DW, et al. Carcinoma of unknown primary site: sequential treatment with paclitaxel/ carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial. Oncology. 2004;9:644-652.
9. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
10. Pouessel D, Culine S, Becht C, et al. Gemcitabine and docetaxel after failure of cisplatin-based chemotherapy in patients with carcinoma of unknown primary site. Anticancer Res. 2003;23:2801-2804.